论文部分内容阅读
目的探讨不同联合用药方案治疗急性脑梗死的疗效。方法选取急性脑梗死患者100例,根据随机数字表法分为观察组和对照组各50例,对照组应用依达拉奉联合丹参治疗,观察组应用依达拉奉联合奥扎格雷治疗,比较2组临床治疗效果。结果治疗后7、14 d时2组患者NIHSS评分均低于治疗前,且观察组低于同期对照组,差异均有统计学意义(P<0.05)。治疗后7、14 d时2组血清CRP、Hcy、MDA水平均低于治疗前,SOD水平高于治疗前,且观察组各项指标改善情况均优于对照组,差异均有统计学意义(P<0.05)。观察组总有效率高于对照组,不良反应发生率低于对照组,差异均有统计学意义(P<0.05)。结论依达拉奉联合奥扎格雷治疗急性脑梗死,效果显著,有利于提高生存质量,降低病死率和不良反应发生率,安全性好,值得临床推广。
Objective To explore the efficacy of different combination regimens in the treatment of acute cerebral infarction. Methods One hundred patients with acute cerebral infarction were selected and divided into observation group and control group according to the random number table method, 50 cases in each group. The control group was treated with edaravone combined with Salvia miltiorrhiza. The observation group was treated with edaravone and ozagrel. 2 groups of clinical treatment effect. Results At 7 and 14 days after treatment, the NIHSS scores of two groups were lower than those before treatment, and the observation group was lower than the control group at the same period (P <0.05). Serum levels of CRP, Hcy and MDA were lower in the two groups at 7 and 14 days after treatment than those before treatment, and the level of SOD was higher than that before treatment, and the improvement of each index in the observation group was better than that in the control group P <0.05). The total effective rate in the observation group was higher than that in the control group, and the incidence of adverse reactions was lower than that in the control group (P <0.05). Conclusion Edaravone combined with ozagrel in the treatment of acute cerebral infarction has significant effect, which is beneficial to improve the quality of life, reduce the incidence of mortality and adverse reactions, safety, and worthy of clinical promotion.